Stock Events

Stock Events

Devonian Health Group 

$7.00
1
+$0.00+0% Wednesday 20:00

Statistics

Day High
7
Day Low
7
52W High
10.8
52W Low
4.27
Volume
100
Avg. Volume
1
Mkt Cap
19.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22DecExpected
Q3 2022
-0.01
0.33
0.66
0.99
Expected EPS
N/A
Actual EPS
-0.0069

Financials

-25.94%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
16.72MRevenue
-4.34MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap179.35M
Corbus Pharmaceuticals develops innovative therapeutics in the area of inflammatory and fibrotic diseases, overlapping with Devonian's therapeutic areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.49B
Acadia Pharmaceuticals specializes in biopharmaceuticals for central nervous system disorders, a field relevant to Devonian's product development.
Supernus Pharmaceuticals
SUPN
Mkt Cap2.81B
Supernus Pharmaceuticals focuses on CNS diseases, directly competing with Devonian's therapeutic focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals works on RNAi therapeutics, competing in the innovative pharmaceuticals space with Devonian.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals engages in creating new drugs for serious diseases, similar to Devonian's mission in botanical-based therapeutics.
Incyte
INCY
Mkt Cap23.32B
Incyte specializes in oncology and inflammatory diseases, areas that Devonian might target with its botanical drugs.
AMGEN
AMGN
Mkt Cap196.12B
Amgen, a biotech giant, competes broadly in the pharmaceuticals market, including areas that might overlap with Devonian's botanical treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is involved in biopharmaceuticals for a variety of therapeutic areas, potentially competing with Devonian's products.

About

Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Show more...
CEO
Dr. Andre P. Boulet Ph.D.
Employees
8
Country
Canada
ISIN
CA2518348834

Listings

OTC Link
US
DVHGF
V
CA
GSD.V

0 Comments

Share your thoughts

FAQ

What is Devonian Health Group stock price today?▼
The current price of DVHGF is $7.00 USD — it has increased by +0% in the past 24 hours. Watch Devonian Health Group stock price performance more closely on the chart.
What is Devonian Health Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Devonian Health Group stocks are traded under the ticker DVHGF.
Is Devonian Health Group stock price growing?▼
DVHGF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Devonian Health Group has showed a -35.19% decrease.
What is Devonian Health Group market cap?▼
Today Devonian Health Group has the market capitalization of 19.46M
What were Devonian Health Group earnings last quarter?▼
DVHGF earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Devonian Health Group revenue for the last year?▼
Devonian Health Group revenue for the last year amounts to 16.72M USD.
What is Devonian Health Group net income for the last year?▼
DVHGF net income for the last year is -4.34M USD.
How many employees does Devonian Health Group have?▼
As of August 12, 2026, the company has 8 employees.
In which sector is Devonian Health Group located?▼
Devonian Health Group operates in the Health & Wellness sector.
When did Devonian Health Group complete a stock split?▼
The last stock split for Devonian Health Group was on January 22, 2026 with a ratio of 1:60.
Where is Devonian Health Group headquartered?▼
Devonian Health Group is headquartered in Québec, Canada.